Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.
Quite frankly if a pump and dump crew turned up and managed to make the price go up then that would give many people who are thinking of exiting a chance to recoup a small amount of money so is probably a good thing.
Doesn't seem to be. Trial leaders are Professor Chris Butler and Professor Richard Hobbs. https://www.phc.ox.ac.uk/research/covid-19/projects/principle-trial
Although it is Oxford so you do have to wonder about John Bell...
Shocking - and all the while we run on without help. Those running the PRINCIPLE trial should be ashamed of themselves that an MSc student was abole to pull apart the original paper's results as being blatantly fraudulent and yet they didn't bother to check.
See some support at this level https://www.tradingview.com/x/0hqQZFNV/
Improve care pathways through improving diagnostic capacity and technology
Both in the UK and globally, there are opportunities to provide earlier access to treatment for respiratory diseases including TB, asthma and COPD through better diagnostics and monitoring technologies that improve clinical understanding of respiratory disease and its underlying causes. Such technology could improve the speed with which individuals can move through clinical pathways and be critical in addressing the burden of respiratory disease in low- and middle-income countries.
For those that are more recent - SNG started out targetting the treatment at viral respiratory disease in Asthma and COPD. Based on this we are well placed even if Covid recedes:
Reducing the mortality and morbidity of respiratory disease, in the UK and globally
Overarching ambition
Reduce the pressure on the NHS and improve clinical outcomes, through driving improvements in the underpinning understanding of respiratory disease, as well as its treatment and diagnosis.
Respiratory disease affects one in five people in the UK. Lung diseases account for approximately 700,000 UK hospital admissions and over 6 million inpatient bed-days each year.[footnote 37] Despite the inclusion of lung health as a clinical priority in the NHS Long Term Plan, outcomes continue to stagnate.
Asthma causes over 1 million severe attacks and 1,400 deaths per year in the UK; two-thirds of these are potentially preventable.[footnote 38] However, in the UK, there is an over-reliance on “rescue” therapies prior to or after an attack, with over 15.5 million blue rescue inhalers prescribed every year, and more than 130,000 people taking at least 3 courses of oral corticosteroids each year.
For chronic obstructive pulmonary disease (COPD), the UK has one of the highest mortality rates worldwide.[footnote 39] COPD is the second largest cause of emergency hospital admission in the UK and costs £1.9 billion per year.[footnote 40] Moreover, five-year survival post-hospitalisation for a COPD exacerbation is lower than most cancers, at only 50%.[footnote 41]
There is a real opportunity to advance the science in this area, and through that significantly reduce the number of attacks, hospitalisations and deaths over the next decade. Therefore, government, industry and NHS England will explore options to do the following.
Create more effective treatment options for asthma, particularly children and young adults
Build on the significant improvements in the understanding of the biological processes that lead to the airway inflammation that causes asthma by identifying new biomarkers for asthma and leverage genetics to better identify populations that will respond to new treatments and support patients with uncontrolled disease.
Drive innovation in the understanding and treatment of COPD
In spite of the high unmet need for COPD, breakthroughs in innovation have been limited, and until recently, no new treatments have shown impact on mortality rates. There is an opportunity to identify disease and intervene earlier and move from symptom control towards disease modification. There are also opportunities for further research into novel targets addressing cell dysfunction, lung tissue damage and airway remodelling, and the potentially transformational role of biologics for certain COPD patients, as well as targeting cell senescence.
Don't get me wrong - I like what they are trying to do but for as long as they are using CLNs to expand it will limit any SP rises. Once they are generating income and able to stand on their own 2 feet then we'll see some improvements